1. A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar
2. Press release: European Medicines Agency recommends approval of first two monoclonal‐antibody biosimilars. Recommendation marks extension of biosimilar concept to new product class. 28 June 2013. Available at:http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1(last accessed 27 December 2017).
3. Biologics for psoriasis: more drugs, new patient categories, but fresh challenges for clinical dermatologists
4. European Medicines Agency.Update of questions and answers on biosimilar medicines. May2012. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2012/05/WC500127917.pdf(last accessed 27 December 2017).
5. Clinical Pharmacokinetics and Use??of??Infliximab